ATEA PHARMACEUTICALS INC
AVIRNASDAQTrading Snapshot
- Day Range
- $5.11 – $5.25
- 52-Week Range
- $2.78 – $6.45
- Volume
- $3.22B
- Avg Volume
- $2.23B
- Shares Outstanding
- 80.0M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $71M
- Last Q Revenue
- $17M
- P/E Ratio
- -2.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.06
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −7.5%
Why Investors Own AVIR
- ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ATEA PHARMACEUTICALS INC
AVIR
StockOtter · stockotter.spaceAbout ATEA PHARMACEUTICALS INC
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeut
BlackRock Inc. Makes New $40.55 Million Investment in Atea Pharmaceuticals, Inc. $AVIR
BlackRock Inc. purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 8,72
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints aga
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV